Redcliffe Lifetech has raised US$ 61 million (approximately ₹468 crore) in Series B round of funding from LeapFrog Investments, HealthQuad, and other investors.
Vertices Partners advised Redcliffe Lifetech.
The team was led by Associate Partners Samrat Roy, Vani Panicker and Vikrant Anand.
Founder & Managing Partner Vinayak Burman provided strategic inputs.
Shardul Amarchand Mangaldas advised LeapFrog Investments.
The team was led by Anuj Bhasme (Partner), Rishikesh Desai (Senior Associate); Apeksha Narula (Associate), Anusha Chand (Associate) and Aakash Rao (Associate). Claire Yuen, Legal Counsel at LeapFrog and Hardik Thakker (Principal Associate at Shardul Amarchand Mangaldas & Co., seconded to LeapFrog) also represented LeapFrog.
Debevoise & Plimpton also acted for LeapFrog as their US Counsel.
DSK Legal advised HealthQuad with a team led by Partner Rishi Anand assisted by Nakul Batra (Associate Partner) and Snigdha Prakash (Associate)
Anoma Legal advised Chiratae Ventures and Alkemi Growth Capital with a team led by Partner Krishna Venkat.
Redcliffe plans to deploy the fresh capital to expand its geographic reach across India, with a focus on expanding its low-cost direct-to-consumer diagnostics into tier II, III and IV cities. The newly infused funds will also be utilized to scale the company’s platform and increase product offerings to radiology, disease data profiling and lifestyle management.